Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Typhon Capital Management and Trevinici Capital Partners to merge

Wednesday, July 30, 2014

Bailey McCann, Opalesque New York:

Chicago-based Typhon Capital Management has completed a merger with Trevinci Capital Partners, the Chicago-based asset management affiliate of America’s largest crop insurance broker, Silveus Insurance Group. The transaction, which was finalized last week, involved Trevinci buying a minority stake in Typhon at a $6m pre-money valuation.

"We’ve known and done business with the principals for many years," Typhon’s CEO, James L. Koutoulas, Esq. said in an interview with Opalesque. "The relationship with Silveus will also be a strategic asset for us."

He notes that Trevinci’s agriculture options trading strategy will be a complement to Typhon’s Plutus grain strategy and Tauros livestock strategy. "The acquisition was a no brainer."

Trevinci’s Chief Operating Officer, Jacob Rossof, and its Chief Risk Officer, Satish Nandapurkar, will serve those same roles across all of Typhon’s principal trading strategies and join Typhon’s investment and risk committees. Trevinci’s Liquid Agricultural Trading Group, led by Cy Monley, will trade exclusively for clients of Typhon, and launched a fund vehicle on Typhon Access’s Hydra managed account platform last month.

The acquisition represents the latest addition in a growing pipeline for Typhon which was founded in 2008. Koutoulas oversees the Typhon Capital Management CTA program as well as the Typhon Access Hydra managed account platform. Koutoulas, a lawyer, also led a pro-bono effort to ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for